What is BPC-157 used for?

What the literature actually examined

A 2025 systematic review (Vasireddi et al.) covering 36 studies published between 1993 and 2024 found consistent effects across musculoskeletal models — and the word doing the work in that sentence is “models”. The studies are surgical: a tendon is cut, an ulcer is induced, a nerve is crushed, and healing is measured against controls. The recurring findings are faster tendon and ligament healing in rats, accelerated recovery in crush and blunt-force muscle injury, protection against NSAID-induced gastric lesions, improved anastomosis healing after gut surgery, better fracture mineralisation, and functional recovery after sciatic nerve transection.

That list is genuinely informative, and it is narrower than “BPC-157 heals tissue”. Every entry is an acute, deliberately-inflicted injury in an animal, measured over days to weeks. None of them is a chronic human tendinopathy, and none is a person with a sore shoulder.

The gastrointestinal work is the oldest and best-founded

BPC-157 was isolated from a protective protein found in gastric juice, which is why the gut research came first and why the compound is unusually stable in stomach acid. That stability is a real, mechanistically-grounded property rather than a marketing claim, and it is the reason oral administration is coherent for gut-directed research where it would make little sense for a tendon. It is also the strongest link in the chain: the compound is being studied in the tissue it was found in.

What a rodent model can and cannot establish

A well-run animal model can establish that a mechanism operates — that a compound changes a measurable healing rate under controlled conditions. What it cannot establish is the three things a reader actually wants: whether the effect appears in humans, at what exposure, and how large it is. Dose scaling between species is not a simple conversion, the injuries are acute rather than chronic, and the endpoints are often histological rather than functional. A mechanism can be entirely real and still not produce a clinically meaningful result in people.

The concentration-of-source problem

This is the single most useful thing to know about the BPC-157 literature and it is rarely mentioned. A large share of the published research originates from one research group — Sikiric and colleagues in Croatia — which means the body of evidence is less independent than a raw study count suggests. Thirty-six studies from many laboratories and thirty-six studies concentrated in a few are different kinds of evidence, and independent replication is what separates them. That is not an accusation of anything; it is a statement about how much the count can carry.

The human record, in full

One Phase 1 safety and pharmacokinetics trial of an oral formulation is registered as NCT02637284. It is registered, and no peer-reviewed results have been published. Beyond that there is a small case series involving a single localised injection. That is the complete human record — which is why the honest answer to what BPC-157 is used for names the models rather than a set of indications.

How the marketed claim was assembled

The path runs: rats with transected tendons healed faster than controls, therefore BPC-157 accelerates tendon healing, therefore BPC-157 is a healing peptide, therefore it works for an injury someone has now. Each step drops a qualifier, and the qualifiers were the content — the species, the injury type, the exposure, the timescale. The step that goes missing every time is the one nobody has taken: a controlled human trial.

• No completed Phase 2 or Phase 3 trial exists for any application.
• The evidence base is animal injury models, reviewed most recently across 36 studies from 1993 to 2024.
• The gastrointestinal work is the oldest and rests on the compound's origin in gastric juice.
• A large share of the literature comes from a single research group, so study count overstates independence.
• The human record is one registered Phase 1 with no published results, plus a small case series.